amrinone has been researched along with cilostazol in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bristol, JA; Cain, MH; Weishaar, RE | 1 |
| Hidaka, H; Inoue, Y; Kimura, Y; Sudo, T; Tachibana, K; Tochizawa, S; Toga, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Sawada, M; Suzumura, A; Takayanagi, T; Tamaru, T; Yoshikawa, M | 1 |
2 review(s) available for amrinone and cilostazol
| Article | Year |
|---|---|
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Calmodulin; Cardiotonic Agents; Guinea Pigs; Humans; Hypersensitivity; In Vitro Techniques; Lung Diseases; Myocardium; Platelet Aggregation; Substrate Specificity | 1985 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for amrinone and cilostazol
| Article | Year |
|---|---|
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Blood Platelets; Cells, Cultured; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Isoenzymes; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinolines; Quinolones; Recombinant Proteins; Semicarbazides; Urea | 2000 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamole; DNA Primers; Gene Expression Regulation, Enzymologic; Interleukin-1; Interleukin-6; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Papaverine; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazines; Pyrrolidinones; Quinolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Rolipram; Tetrazoles; Theophylline; Tumor Necrosis Factor-alpha; Vinca Alkaloids; Xanthines | 1999 |